PMID- 23608237
OWN - NLM
STAT- MEDLINE
DCOM- 20131024
LR  - 20181202
IS  - 1879-355X (Electronic)
IS  - 0360-3016 (Linking)
VI  - 87
IP  - 1
DP  - 2013 Sep 1
TI  - Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic 
      impact on locoregional control.
PG  - 60-6
LID - S0360-3016(13)00269-1 [pii]
LID - 10.1016/j.ijrobp.2013.03.008 [doi]
AB  - PURPOSE: To evaluate the influence of elective inguinal node radiation therapy 
      (INRT) on locoregional control (LRC) in patients with early-stage T2N0 anal 
      cancer treated conservatively with primary RT. METHODS AND MATERIALS: Between 
      1976 and 2008, 116 patients with T2 node-negative anal cancer were treated 
      curatively with RT alone (n=48) or by combined chemoradiation therapy (CRT) 
      (n=68) incorporating mitomycin C and 5-fluorouracil. Sixty-four percent of the 
      patients (n=74) received elective INRT. RESULTS: Over a median follow-up of 69 
      months (range, 4-243 months), 97 (84%) and 95 patients (82%) were locally and 
      locoregionally controlled, respectively. Rates for 5-year actuarial local 
      control, LRC, cancer-specific, and overall survival for the entire population 
      were 81.7% +/- 3.8%, 79.2% +/- 4.1%, 91.1% +/- 3.0%, and 72.1% +/- 4.5%, respectively. 
      The overall 5-year inguinal relapse-free survival was 92.3% +/- 2.9%. Isolated 
      inguinal recurrence occurred in 2 patients (4.7%) treated without INRT, whereas 
      no groin relapse was observed in those treated with INRT. The 5-year LRC rates 
      for patients treated with and without INRT and with RT alone versus combined CRT 
      were 80.1% +/- 5.0% versus 77.8% +/- 7.0% (P=.967) and 71.0% +/- 7.2% versus 85.4% +/- 
      4.5% (P=.147), respectively. A trend toward a higher rate of grade >/=3 acute 
      toxicity was observed in patients treated with INRT (53% vs 31%, P=.076). 
      CONCLUSIONS: In cases of node-negative T2 anal cancer, the inguinal relapse rate 
      remains relatively low with or without INRT. The role of INRT in the treatment of 
      early-stage anal carcinoma needs to be investigated in future prospective trials.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Zilli, Thomas
AU  - Zilli T
AD  - Department of Radiation Oncology, Geneva University Hospital, Geneva, 
      Switzerland. Thomas.Zilli@hcuge.ch
FAU - Betz, Michael
AU  - Betz M
FAU - Bieri, Sabine
AU  - Bieri S
FAU - Ris, Frederic
AU  - Ris F
FAU - Roche, Bruno
AU  - Roche B
FAU - Roth, Arnaud D
AU  - Roth AD
FAU - Allal, Abdelkarim S
AU  - Allal AS
LA  - eng
PT  - Journal Article
DEP - 20130419
PL  - United States
TA  - Int J Radiat Oncol Biol Phys
JT  - International journal of radiation oncology, biology, physics
JID - 7603616
RN  - 50SG953SK6 (Mitomycin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
CIN - Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):13-5. PMID: 23920385
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Anus Neoplasms/drug therapy/pathology/*radiotherapy
MH  - Carcinoma, Squamous Cell/drug therapy/pathology/*radiotherapy
MH  - Carcinoma, Transitional Cell/pathology/*radiotherapy/surgery
MH  - Chemoradiotherapy/methods
MH  - Dose Fractionation, Radiation
MH  - Female
MH  - Fluorouracil/administration & dosage
MH  - Humans
MH  - Inguinal Canal
MH  - Lymphatic Irradiation/*methods
MH  - Male
MH  - Middle Aged
MH  - Mitomycin/administration & dosage
MH  - Neoplasm Staging
MH  - Retrospective Studies
EDAT- 2013/04/24 06:00
MHDA- 2013/10/25 06:00
CRDT- 2013/04/24 06:00
PHST- 2012/10/25 00:00 [received]
PHST- 2013/03/04 00:00 [revised]
PHST- 2013/03/06 00:00 [accepted]
PHST- 2013/04/24 06:00 [entrez]
PHST- 2013/04/24 06:00 [pubmed]
PHST- 2013/10/25 06:00 [medline]
AID - S0360-3016(13)00269-1 [pii]
AID - 10.1016/j.ijrobp.2013.03.008 [doi]
PST - ppublish
SO  - Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):60-6. doi: 
      10.1016/j.ijrobp.2013.03.008. Epub 2013 Apr 19.